Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Multidisciplinary management of X-linked myotubular myopathy in Spain and Portugal: A case series analysis.

Neurologia·2026
Same author

Correction: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

Oncogene·2025
Same author

Editorial Expression of Concern: Heat shock protein 27 confers resistance to androgen ablation and chemotherapy in prostate cancer cells through eIF4E.

Oncogene·2025
Same author

Microscopic fractional anisotropy outperforms multiple sclerosis lesion assessment and clinical outcome associations over standard fractional anisotropy tensor.

Human brain mapping·2024
Same author

A pivotal role for the IL-1β and the inflammasome in preterm labor.

Scientific reports·2024
Same author

Synthetic MRI in subarachnoid haemorrhage.

Clinical radiology·2021

Related Experiment Video

Updated: May 6, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

2.2K

Quantifying Gp96/Grp94 complexes preparations for vaccines: a key step often inaccurate.

A Seignez1, É Kohli, C Garrido

  • 1Carmen Garrido, INSERM U866, Faculty of Medicine and Pharmacy, 7 boulevard Jeanne D'Arc, 21079 Dijon, France. cgarrido@u-bourgogne.fr.

Current Medicinal Chemistry
|October 30, 2013
PubMed
Summary

Glycoprotein 96 (Gp96)-peptide complexes show promise for cancer vaccines by stimulating immunity. This review covers Gp96

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.3K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.9K

Related Experiment Videos

Last Updated: May 6, 2026

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen
07:44

Fabrication of Pulsatile Polymeric Microparticles Encapsulating Rabies Antigen

Published on: May 12, 2023

2.2K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

21.3K
Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development
12:53

Cell-Free Scaled Production and Adjuvant Addition to a Recombinant Major Outer Membrane Protein from Chlamydia muridarum for Vaccine Development

Published on: March 16, 2022

2.9K

Area of Science:

  • Immunology and Cancer Therapy
  • Molecular Chaperones in Immunity

Background:

  • Glycoprotein 96 (Gp96), also known as tumor rejection antigen (TRA)-1, is investigated for cancer vaccine development.
  • Gp96-peptide complexes elicit immune responses, protecting against tumors in a haplotype-dependent manner.
  • Secreted Gp96-peptide complexes function as danger signals, activating innate immunity independently of the peptides.

Purpose of the Study:

  • To review the application of the chaperone Gp96 in cancer vaccination strategies.
  • To discuss the dual role of Gp96-peptide complexes in innate immunity and tumor rejection.
  • To detail current methods for quantifying Gp96-peptide preparations, highlighting their limitations.

Main Methods:

  • Review of existing literature on Gp96-peptide complexes in cancer therapy.
  • Analysis of Gp96's mechanism of action in stimulating innate and adaptive immunity.
  • Evaluation of purification techniques and quantification assays for Gp96-peptide complexes.

Main Results:

  • Gp96-peptide complexes possess dual functions: danger signaling via innate immunity and peptide-dependent tumor rejection.
  • The tumor rejection antigen activity of Gp96-peptide complexes is mediated by chaperoned peptides in a dose-dependent manner.
  • Current purification and quantification methods for Gp96-peptide complexes are often suboptimal.

Conclusions:

  • Gp96-peptide complexes are a significant area of research for developing novel cancer vaccines.
  • Understanding the purification and quantification of these complexes is critical for their therapeutic application.
  • Further refinement of quantification methods is needed to ensure the quality and efficacy of Gp96-based vaccines.